BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
WALTHAM, Mass., April 27, 2017 -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31, 2017, on May 11, 2017 before the market opens.
Histogenics’ management will host a conference call on Thursday, May 11, 2017 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “97247103” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the presentation.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
